This site is intended for healthcare professionals
Login | Register (NOW FREE)

Medical search

leflunomide for rheumatoid arthritis

FREE subscriptions for doctors and students... click here
You have 3 open access pages.

  • leflunomide is a disease-modifying drug (DMARD) that is licensed for the treatment of active rheumatoid arthritis (RA) in adults

  • evidence suggests that leflunomide is an effective DMARD for adults with active RA; the benefits of treatment are evident as improvement in tender and swollen joints - these benefits are evident by 4 weeks after starting treatment

  • in comparison with methotrexate or sulphasalazine, leflunomide appears to be similarly effective - however leflunomide appears to more likely to cause unwanted effects

  • unwanted effects with leflunomide appear to be more likely if given concomitantly with, or started just after switching from, another DMARD with a similar toxity profile; unwanted effects appear to be more likely if there is a switch to another DMARD without elimination of leflunomide's active metabolite

  • because of the long half-life of leflunomide it takes a long time to achieve a steady-state concentration

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  • (1) Drug and Therapeutics Bulletin 2000; 38 (7):52-4.

Links:

The information provided herein should not be used for diagnosis or treatment of any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2016 Oxbridge Solutions Ltd®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions Ltd® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.